Exemestane Shortage: What Providers and Prescribers Need to Know in 2026

Patients taking exemestane (Aromasin) for hormone receptor-positive breast cancer are increasingly reporting difficulty filling their prescriptions in 2026. As the prescribing provider, understanding the supply landscape — and having a protocol to manage it — is essential for maintaining treatment continuity and preventing unintended lapses in adjuvant hormonal therapy.

Current Supply Status: Not an FDA-Declared Shortage — But Real Pharmacy Gaps Exist

As of 2026, exemestane does not appear on the FDA Drug Shortages Database, indicating no manufacturer-level supply disruption has been officially reported. However, pharmacy-level stockouts — driven by thin stocking of this lower-volume drug — are creating meaningful access problems for patients in multiple regions.

The root causes are structural rather than crisis-driven:

• Exemestane represents a small fraction of AI prescriptions nationally — anastrozole and letrozole are far more commonly prescribed, so pharmacies stock exemestane in smaller quantities
• Generic manufacturers have consolidated since patent expiry — fewer active manufacturers means less supply-chain redundancy
• Insurance and prior authorization delays are sometimes mistaken for supply problems by both patients and front-line pharmacy staff

Clinical Context: Why Therapy Continuity Matters

Exemestane is prescribed as long-term adjuvant therapy — typically 5 years, and in some cases extended to 7–10 years following recommendations from extended adjuvant trials. Its protective effect is cumulative and dependent on consistent estrogen suppression. Brief lapses of 1–2 days are unlikely to meaningfully compromise outcomes; lapses of several weeks may.

Studies including the Intergroup Exemestane Study (IES) and MA.27 data demonstrate that switching to exemestane from 2–3 years of tamoxifen significantly reduces recurrence and improves disease-free survival. This benefit is contingent on adherence. Patient-reported non-adherence due to access barriers is a recognized problem in adjuvant AI therapy.

When a Switch to Anastrozole or Letrozole Is Appropriate

The MA.27 trial (7,576 postmenopausal women with HR+ early breast cancer) found no significant difference in event-free survival between 5 years of exemestane and anastrozole as initial adjuvant therapy. A 2025 French cohort study (JAMA Network Open) found slightly better DFS and OS with anastrozole and letrozole over exemestane at 8 years, though differences were modest.

Switching to a nonsteroidal AI may be appropriate when:

• The patient was initiated on exemestane as first-line adjuvant therapy (not after nonsteroidal AI failure)
• Supply disruption will persist beyond 5–7 days
• The patient has not previously failed a nonsteroidal AI

A switch is generally NOT appropriate when:

• Exemestane was initiated specifically because the patient failed or was intolerant of anastrozole or letrozole
• The patient has documented disease progression on a nonsteroidal AI (non-cross resistance between steroidal and nonsteroidal classes is a key clinical rationale for exemestane)
• The patient is on the sequential tamoxifen → exemestane protocol in a clinical trial

Operational Recommendations for Your Practice

Consider implementing the following protocols when patients on exemestane report access difficulties:

1. Proactive refill counseling. Counsel patients to refill exemestane 7–10 days before their supply runs out, not on the last day. Maintaining a buffer is especially important for this medication.
2. 90-day supply prescriptions. Write for 90-day supplies when insurance allows. Mail-order pharmacies stock exemestane reliably and typically at lower cost. This reduces refill frequency and the risk of gaps.
3. Preferred pharmacy relationships. Your oncology practice or cancer center's outpatient pharmacy likely stocks exemestane reliably. Routing at-risk patients there can prevent access problems.
4. medfinder for patient navigation. medfinder.com/providers is a service that contacts pharmacies near a patient to find which ones have a medication in stock. This can save significant time for both your staff and the patient.
5. Sample inventory. Keep a modest sample stock on hand if your practice is able to, for bridging patients who are experiencing access gaps.

Prior Authorization Issues

Some commercial plans and Medicare Part D plans require prior authorization for exemestane, particularly when a patient has not yet tried anastrozole or letrozole (step therapy protocols). If your patient is encountering insurance barriers:

• Submit detailed clinical documentation — including prior AI use, intolerance, or the tamoxifen-switch protocol justification
• Request peer-to-peer review if the initial prior auth is denied
• Use the Pfizer patient assistance or manufacturer programs if insurance coverage fails entirely

Additional Resources for Your Practice

Read our detailed provider guide: How to Help Your Patients Find Exemestane in Stock. It covers pharmacy navigation strategies, patient assistance programs, and recommendations for maintaining treatment continuity.